arrow
P

Philippe Barthélémy

university hospital of strasbourg
H指数:31
被引数:4,875

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer

探索与转移性去势抵抗性前列腺癌患者从talazoparib单药治疗中获益延长或耐药相关的肿瘤基因组学研究

2026-09-290
OA
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3trial

Nivolumab联合多西他赛与安慰剂联合多西他赛治疗雄激素受体通路抑制剂预处理和化疗初免的转移性去势抵抗性前列腺癌 (CheckMate 7DX): 一项双盲,随机,3期试验

2026-01-010
PRE
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy

Talazoparib单药治疗具有DNA损伤应答改变的转移性去势抵抗性前列腺癌——与治疗反应相关的基因组特征

2025-10-300
PRE
Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)

tivozanib (TIVO) 治疗肾细胞癌 (RCC) 的综合疗效与安全性暴露反应 (ER) 分析

2025-10-010
OAAI
Updated 2025 French guidelines for renal cell carcinoma
2025-10-010
OAAI
Pembrolizumab plus lenvatinib for previously untreated advanced non-clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study

帕博利珠单抗联合仑伐替尼用于初治的透明细胞肾细胞癌以外的晚期肾细胞癌:KEYNOTE-B61研究的3年随访结果

2025-10-012
OAAI
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)

tivozanib (tivo) 在转移性肾细胞癌 (mRCC) 患者中 III 期临床试验的安全性概述

2025-10-010
OAAI
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study

肾细胞癌辅助免疫治疗和复发管理的现状:欧洲德尔菲研究的见解

2025-06-070
PRE
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial

avelumab为基础的新辅助疗法在肌肉浸润性膀胱癌患者中的应用(AURA Oncodistinct-004):一项多中心二期临床试验

2025-05-240
OA
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

在随机UNIRAD试验中,根据内分泌治疗基础方案,辅助依维莫司的差异化获益

2025-05-010
OAAI
Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients

晚期转移性膀胱癌患者与临床医生报告症状的一致性

2025-04-210
OAAI
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial

在多中心、随机CABASTY试验中,老年转移性去势抵抗性前列腺癌患者采用每两周 versus 每三周卡巴他赛方案时的疼痛与健康状况相关生活质量。

2025-02-010
OAAI
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

2024-11-010
OAAI
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3TiNivo-2 Study

免疫检查点抑制剂后肾细胞癌患者Tivozanib联合nivolumab与tivozanib单药治疗的比较: 3TiNivo-2期研究的结果

LANCET
IF88.5
2024-10-014
PRE
Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results

Opevesostat (MK-5684/ODM-208),一种口服CYP11A1抑制剂,在转移性去势抵抗性前列腺癌(mCRPC)中的应用:CYPIDES II期研究的更新结果

2024-09-010
PRE
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
2024-08-010
PRE